Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors
Licciardello, M. P.; Zhang, C.; Le, A. T.; Doebele, R. C.; Clarke, P. A.; Workman, P.
Show abstract
Heat Shock Protein 90 inhibitors (HSP90i) have shown activity in EML4-ALK+ non-small cell lung cancer (NSCLC) patients but clinical responses have been heterogeneous. It has been suggested that distinct EML4-ALK variants may have a differential impact on the response to HSP90 inhibition. Here, we show that NSCLC cells harboring the most common EML4-ALK variant 1 (v1) or variant 3 (v3) are in fact similarly sensitive to HSP90i. To discover new genetic alterations that could be involved in stratifying sensitivity, we performed a genome-wide CRISPR/Cas9 knockout screen and found that loss of Spindly increases the sensitivity of EML4-ALK v3, but not v1, NSCLC cells to low concentrations of HSP90i from three distinct chemical families. Upon loss of Spindly, prolonged exposure to low concentrations of HSP90i impairs chromosome congression and cellular fitness. Collectively, our data suggest that mutations leading to loss of Spindly in EML4-ALK v3 NSCLC patients may increase sensitivity to low doses of HSP90i.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53 96%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 95%
- PIM Kinases Alter Mitochondrial Dynamics and Chemosensitivity in Lung Cancer 95%
Similar papers in this journal
- The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling 96%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 96%
- Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes 95%
Similar papers in this journal
Similar papers in this journal
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status 96%
- Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity 96%
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.